Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(02): 227-233
DOI: 10.4103/ijmpo.ijmpo_99_17
Review Article

Neoadjuvant Chemotherapy for Larynx Preservation: Has it Lost Importance?

Rony Benson
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Supriya Mallick
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
,
G K Rath
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Over the time, the aim of treatment for locally advanced laryngeal and hypopharyngeal carcinoma has changed from cure to cure with the functional larynx. Chemoradiation has emerged as the most important therapeutic modality for patients with locally advanced disease. However, systemic failure remains an important area of concern. Induction chemotherapy has emerged as promising organ preservation approach as it gives an window to select responders and continuing treatment with nonsurgical approach as well as reduces systemic recurrence and improve survival with a functional larynx. However, there are questions about the efficacy of this approach. In this context, we aim to evaluate the trials for locally advanced laryngeal and hypopharyngeal cancer attempting to optimize therapeutic outcome with addition of induction chemotherapy. This present review intends to look into the therapeutic ratio of induction chemotherapy for disease control, organ preservation.

Keywords

Chemoradiotherapy - induction chemotherapy - larynx preservation - locally advanced laryngeal carcinoma - squamous cell carcinoma


Publication History

Article published online:
23 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
    CrossrefPubMedGoogle Scholar
  • 2 Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010; 15: 355-73
    CrossrefPubMedGoogle Scholar
  • 3 Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data MACH-NC Collaborative Group Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55
    CrossrefPubMedGoogle Scholar
  • 4 Pignon JP, le MaîtreA, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14
    CrossrefPubMedGoogle Scholar
  • 5 Aydil U, Akmansu M, Gumusay Ö, Bakkal FK, Yazici Ö, Kizil Y. et al. Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer. Eur Arch Otorhinolaryngol 2016; 273: 2795-803
    CrossrefPubMedGoogle Scholar
  • 6 Department of Veterans Affairs Laryngeal Cancer Study Group. Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M. et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90
    CrossrefPubMedGoogle Scholar
  • 7 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W. et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8
    CrossrefPubMedGoogle Scholar
  • 8 Joshi P, Patil V, Joshi A, Norohna V, Chaturvedi P, Chaukar D. et al. Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma. Indian J Cancer 2013; 50: 25-30
    CrossrefPubMedGoogle Scholar
  • 9 Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A. et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 2009; 119: 1510-7
    CrossrefPubMedGoogle Scholar
  • 10 Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C. et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol 2013; 31: 853-9
    CrossrefPubMedGoogle Scholar
  • 11 Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-9 J Natl Cancer Inst 1996; 88: 890-9
    CrossrefPubMedGoogle Scholar
  • 12 Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J. et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498-506
    CrossrefPubMedGoogle Scholar
  • 13 Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L. et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101: 142-52
    CrossrefPubMedGoogle Scholar
  • 14 Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L. et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012; 23: 2708-14
    CrossrefPubMedGoogle Scholar
  • 15 Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R. et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12: 153-9
    CrossrefPubMedGoogle Scholar
  • 16 Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15
    CrossrefPubMedGoogle Scholar
  • 17 Vermorken JB, Remenar E, van HerpenC, Gorlia T, Mesia R, Degardin M. et al Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704
    CrossrefPubMedGoogle Scholar
  • 18 Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T. et al. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Strahlenther Onkol 2011; 187: 15-22
    CrossrefPubMedGoogle Scholar
  • 19 Rubio SuárezA, Teigeiro NúñezV, Gallo TeránJ, Señaris GonzálezB, Mesuro DomínguezN. Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: Results of a phase II study. Acta Otorrinolaringol Esp 2003; 54: 697-703
    CrossrefPubMedGoogle Scholar
  • 20 Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R. et al. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas – A possibility for organ preservation. Radiother Oncol 2003; 68: 163-70
    CrossrefPubMedGoogle Scholar
  • 21 Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C. et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 2006; 24: 593-8
    CrossrefPubMedGoogle Scholar
  • 22 Céruse P, Cosmidis A, Belot A, Rabilloud M, Fuchsmann C, Poupart M. et al. A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: A multicenter, retrospective study. Anticancer Drugs 2014; 25: 970-5
    CrossrefPubMedGoogle Scholar
  • 23 Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D. et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998; 34: 224-8
    CrossrefPubMedGoogle Scholar
  • 24 Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF. et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31: 845-52
    CrossrefPubMedGoogle Scholar
  • 25 Yoon TM, Lee JK, Cho JS, Lim SC, Chung WK. Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer. 2010;39:142-9 J Otolaryngol Head Neck Surg 2010; 39: 142-9
    Google Scholar
  • 26 Franchin G, Vaccher E, Politi D, Minatel E, Gobitti C, Talamini R. et al. Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. Eur Arch Otorhinolaryngol 2009; 266: 719-26
    CrossrefPubMedGoogle Scholar
  • 27 Prades JM, Lallemant B, Garrel R, Reyt C, Schmitt T. et al. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 2010; 130: 150-5
    CrossrefPubMedGoogle Scholar
  • 28 Andreadis C, Iliopoulou C, Sidiras T, Boutis A, Diamantopoulos N, Vahtsevanos K. et al. Neoadjuvant chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy for larynx preservation in patients with advanced laryngeal cancer. J BUON 2007; 12: 341-7
    PubMedGoogle Scholar